Santantonio Teresa, Wiegand Johannes, Gerlach J Tilman
Clinic of Infectious Diseases, University of Bari, Policlinico, Bari, Italy.
J Hepatol. 2008 Oct;49(4):625-33. doi: 10.1016/j.jhep.2008.07.005. Epub 2008 Jul 17.
The acute phase of hepatitis C virus (HCV) infection represents a key point in the evolution of hepatitis C. In some patients, the infection resolves spontaneously, whereas in others it develops into chronic disease. However, because acute hepatitis C is often asymptomatic, detection and diagnosis are usually difficult. What is more, there are no established treatment guidelines, leaving physicians to make several challenging decisions, such as whether to treat, when to treat and what treatment regimen to use. Pegylated interferon alfa monotherapy is most commonly used to treat patients with acute hepatitis C; the role of ribavirin has yet to be established. In this review, we discuss the epidemiology of acute hepatitis C, its risk factors and routes of transmission and current treatment practices. We also discuss data from published clinical studies and focus on unresolved issues for which additional studies are needed in order to establish standardized treatment guidelines for the management of acute hepatitis C.
丙型肝炎病毒(HCV)感染的急性期是丙型肝炎发展过程中的一个关键点。在一些患者中,感染会自发消退,而在另一些患者中则会发展为慢性疾病。然而,由于急性丙型肝炎通常没有症状,检测和诊断往往很困难。此外,目前还没有既定的治疗指南,这使得医生要做出几个具有挑战性的决定,比如是否治疗、何时治疗以及采用何种治疗方案。聚乙二醇化干扰素α单药疗法是治疗急性丙型肝炎患者最常用的方法;利巴韦林的作用尚未明确。在这篇综述中,我们讨论了急性丙型肝炎的流行病学、其危险因素和传播途径以及当前的治疗方法。我们还讨论了已发表的临床研究数据,并重点关注了一些尚未解决的问题,为了建立急性丙型肝炎管理的标准化治疗指南,还需要进行更多的研究。